Streamlining Aetna Keytruda Prior Authorization Workflows

Navigating Aetna Keytruda Prior Authorization

Keytruda (pembrolizumab) is a vital immunotherapy often requiring prior authorization across Aetna's commercial, Medicare Advantage, and Medicaid managed care plans. Efficiently managing these requests is paramount to ensure timely patient access to this high-cost oncology biologic. Klivira provides a centralized platform to navigate Aetna's specific requirements for specialty medications.

Aetna Prior Authorization Submission Channels for Keytruda

Aetna utilizes various channels for prior authorization, depending on the benefit category and line of business. For medical benefit requests, including many specialty injectables like Keytruda, the primary submission route is often through the Availity provider portal. Aetna also supports X12 278 transactions via clearinghouses for applicable procedure categories, offering an electronic option for integration.

Key Aetna PA Submission Channels

• Availity provider portal for medical benefit prior authorizations.
• X12 278 electronic transactions for integrated system submissions.
• CoverMyMeds or Surescripts ePA for pharmacy benefit specialty medications, if applicable.
• CVS Caremark's direct provider portal for mail-order pharmacy benefit scenarios.

Aetna Clinical Policy Criteria for Keytruda and Other Biologics

Aetna's medical necessity criteria for specialty medications like Keytruda are detailed in their Clinical Policy Bulletins (CPBs), publicly available in the Aetna CPB library. These CPBs are versioned and serve as the canonical source for coverage requirements, including specific indications, dosing, and step therapy protocols. Efficient PA workflows necessitate direct integration with these policy libraries to ensure compliance.

Turnaround Time Expectations for Aetna Keytruda PAs

Prior authorization turnaround times for Aetna are influenced by state-specific regulations, NCQA Utilization Management accreditation standards, and payer-published service-level targets. For Medicare Advantage and Medicaid managed-care plans, CMS-0057-F mandates specific decision timeframes, including 72 hours for standard and 24 hours for expedited requests, impacting the processing of high-volume drugs like Keytruda.

Common Denial Reasons and Appeal Pathways for Keytruda with Aetna

Denials for Keytruda prior authorizations with Aetna often stem from issues such as insufficient documentation of medical necessity, lack of adherence to step therapy protocols, or off-label use without compendium support. Klivira helps identify these common pitfalls before submission, but when denials occur, Aetna provides a clear appeal pathway including reconsideration, peer-to-peer review, and formal appeals.

Typical Aetna Keytruda Denial Categories

• Lack of documented medical necessity or insufficient clinical information.
• Failure to meet step therapy requirements as outlined in Aetna CPBs.
• Off-label use without supporting evidence from recognized compendia.
• Benefit exclusion or site-of-service mismatch.
• Timely filing non-compliance for initial requests or appeals.